TRANSHIATAL ESOPHAGECTOMY IS NOT ASSOCIATED WITH POOR QUALITY LYMPHADENECTOMY

Carregando...
Imagem de Miniatura
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
COLEGIO BRASILEIRO CIRURGIA DIGESTIVA-CBCD
Citação
ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY, v.32, n.4, article ID e1475, 4p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Esophageal cancer neoadjuvant therapy followed by surgery increases the likelihood of treatment success. Aim: To evaluate variables that can influence the number of retrieved lymph nodes, the number of retrieved metastatic lymph nodes and lymphnodal recurrence in esophagectomy after neoadjuvant chemoradiotherapy. Methods: Patients of a single institute were evaluated after completion of trimodal therapy. Univariate and multivariate analyses were performed to evaluate variables that can influence in the number of retrieved lymph nodes and retrieved metastatic lymph nodes. Results: One hundred and forty-nine patients were included. Thoracoscopy access was considered an independent factor for the number of lymph nodes retrieved, but was neither related to the number of positive lymph nodes retrieved nor to lymphnodal recurrence. Pathological complete response on the primary tumor and male were independent variables associated with the number of positive lymph node retrieved. Pathological complete response on the primary tumor site did not statistically influence the likelihood of a lower number of lymph nodes retrieved. Conclusion: Patients submitted to esophagectomy after neoadjuvant chemoradiotherapy, thoracoscopic access is more accurate for pathological staging, even in a complete pathological response. With a proper patient selection, transhiatal surgery may preserve the quality of lymphadenectomy of the positive lymph nodes.
Palavras-chave
Esophageal neoplasms, Neoadjuvant therapy, Esophagectomy
Referências
  1. Fontan AJA, 2018, ABCD-ARQ BRAS CIR DI, V31, DOI 10.1590/0102-672020180001e1382
  2. Almhanna K, 2016, J GASTROINTEST ONCOL, V7, P387, DOI 10.21037/jgo.2015.12.02
  3. Andreollo NA, 2018, ABCD-ARQ BRAS CIR DI, V31, DOI 10.1590/0102-672020180001e1405
  4. Avital S, 2005, AM J SURG, V190, P69, DOI 10.1016/j.amjsurg.2004.12.004
  5. Braghetto I, 2017, ABCD-ARQ BRAS CIR DI, V30, P267, DOI 10.1590/0102-6720201700040010
  6. Bustamante-Lopez LA, 2018, INT J SURG, V56, P283, DOI 10.1016/j.ijsu.2018.07.001
  7. Colvin H, 2011, INTERACT CARDIOV TH, V12, P265, DOI 10.1510/icvts.2010.252148
  8. Darling G, 2009, J SURG ONCOL, V99, P189, DOI 10.1002/jso.21209
  9. Hagens ERC, 2017, J THORAC DIS, V9, pS713, DOI 10.21037/jtd.2017.07.42
  10. Ichimasa K, 2017, MOL CLIN ONCOL, V6, P517, DOI 10.3892/mco.2017.1172
  11. Ivano FH, 2017, ABCD-ARQ BRAS CIR DI, V30, P244, DOI 10.1590/0102-6720201700040004
  12. Kang CH, 2007, EUR J CARDIO-THORAC, V31, P154, DOI 10.1016/j.ejcts.2006.10.033
  13. LOPES Lilian Pinheiro, 2018, ABCD, arq. bras. cir. dig., V31, pe1359, DOI 10.1590/0102-672020180001e1359
  14. Mota FC, 2018, INT J SURG, V54, P176, DOI 10.1016/j.ijsu.2018.04.053
  15. Napier KJ, 2014, WORLD J GASTRO ONCOL, V6, P112, DOI 10.4251/wjgo.v6.i5.112
  16. Rice TW, 2017, ANN CARDIOTHORAC SUR, V6, P119, DOI 10.21037/acs.2017.03.14
  17. Sun Y, 2018, INT J ENDOCRINOL, V2018
  18. Takeuchi H, 2012, ANN THORAC CARDIOVAS, V18, P306, DOI 10.5761/atcs.ra.12.01951
  19. Tanaka Y, 2018, ANN GASTROENT SURG, V2, P253, DOI 10.1002/ags3.12174
  20. Toneto MG, 2018, ABCD-ARQ BRAS CIR DI, V31, DOI 10.1590/0102-672020180001e1373
  21. Van der Werf LR, 2018, ANN SURG ONCOL, V25, P1211, DOI 10.1245/s10434-018-6396-7
  22. van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088
  23. Zhao YM, 2017, ONCOTARGET, V8, P62231, DOI 10.18632/oncotarget.19258